I thought there was a Cyclacel thread, but couldn't find one. We should probably make one . . . for now, parking this new hire here:
>>Cyclacel Pharmaceuticals Announces Appointment of Distinguished Pharma Executive as Senior Vice President, Research
Wednesday June 27, 4:05 pm ET
BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) announced today that Gregory R. Reyes, M.D., Ph.D. has joined the company as Senior Vice President, Research. Dr. Reyes has more than 22 years of experience in leadership roles at a number of biotechnology and pharmaceutical companies including Schering-Plough and, most recently, Pfizer, where he served as Vice President, Biology, Discovery Research, within Pfizer Global Research & Development.
"Greg brings to Cyclacel a successful record of managing world-class drug discovery groups. His broad research background and strong translational skills will provide continued leadership for Cyclacel's scientific team and build on the legacy of achievement by Dr. Bob Jackson, who recently retired at age 64. Greg will be working closely with our Chief Scientist, Professor David Glover, a world authority on mitosis or cell division. Their complementary skills will be of great value as we continue to pursue our discovery programs targeting aurora and polo kinases. Together with a recently completed expansion of our clinical development team under the leadership of Judy Chiao, M.D. we are well positioned to exploit the multiple opportunities ahead as we continue to build shareholder value," said Spiro Rombotis, President and Chief Executive Officer of Cyclacel. "We are delighted to have Greg join us as we progress our three orally-available cell cycle drug candidates, sapacitabine, seliciclib and CYC116, through clinical development and especially as we continue our efforts to create value from the rest of our pipeline."
During his tenure at Pfizer Global Research & Development's Ann Arbor site, Dr. Reyes had responsibility for delivering the annual contribution of new chemical entities and biotherapeutics from the site. He supervised several hundred employees working in multiple therapeutic areas. Dr. Reyes was a member of Pfizer's global discovery research management teams which were responsible for the development and implementation of Pfizer's worldwide discovery research strategy. Before Pfizer, Dr. Reyes served as Vice President, Biological Research, Infectious Diseases and Tumor Biology at Schering-Plough Research Institute (SPRI) and was a member of SPRI's Executive Committee. At Schering-Plough, where he supervised approximately two hundred scientists, his primary responsibilities included setting strategic direction, priorities, and ongoing review of drug discovery programs in oncology and anti-infectives resulting in 14 new drug candidates progressing into preclinical and clinical development. Prior to Schering-Plough Dr. Reyes served as Vice President, Research and Development at Ingenex, Inc., Vice President, Molecular and Biological Research at Triplex Pharmaceuticals, Inc. and Vice President, Hepatitis Research at GeneLabs, Inc. where he pursued multiple oncology and antiviral programs from discovery to clinical trials.
Dr. Reyes earned his B.A. summa cum laude in Biology from the University of California at Santa Cruz in 1976, his M.D. and Ph.D. from The Johns Hopkins School of Medicine in 1982, completed his internship at Stanford University Hospital in 1983 and was Damon Runyon-Walter Winchell Cancer Fund Postdoctoral Fellow at Stanford University Hospital. He has received numerous awards and distinctions and was recently appointed by the Director of the National Institutes of Health (NIH) to the National Advisory General Medical Sciences Council for a four year term ending in December 2007.<<
snip
Cheers, Tuck |
